Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Kees

Showing results (141-150 of 376) with videos related to

Pageof 38
Sort By:
European Heart Journal|January 14, 2016
Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 studyJohn J P Kastelein, Steven E Nissen, Daniel J Rader, et al.
Journal of Clinical Lipidology|October 6, 2018
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, John R Guyton, Gisle Langslet, et al.
Circulation. Genomic and Precision Medicine|December 19, 2018
A Deep Intronic Variant in LDLR in Familial HypercholesterolemiaLaurens F Reeskamp, Merel L Hartgers, Jorge Peter, et al.
Journal of Clinical Lipidology|July 29, 2018
Ethnic differences in plasma lipid levels in a large multiethnic cohort: The HELIUS studyKatia Gazzola, Marieke B Snijder, G Kees Hovingh, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 9, 2025
Therapeutic drug monitoring of piperacillin: Agreement between quantitative nuclear magnetic resonance spectroscopy and liquid chromatography with tandem mass spectrometryAlexander Dejaco, Michael Paal, Michael Gruber, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 19, 2016
Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief ReportRutger Verbeek, Marjorie Boyer, S Matthijs Boekholdt, et al.
Journal of Clinical Lipidology|October 26, 2017
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, Frederick J Raal, Ricardo Dent, et al.
Journal of Lipid Research|April 18, 2003
The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemiaG Kees Hovingh, Michel J A Van Wijland, Alison Brownlie, et al.
Circulation Research|July 19, 2014
Mutations in STAP1 are associated with autosomal dominant hypercholesterolemiaSigrid W Fouchier, Geesje M Dallinga-Thie, Joost C M Meijers, et al.
Therapeutic Drug Monitoring|September 16, 2016
Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug InteractionsChristoph Töpper, Cathérine L Steinbach, Christoph Dorn, et al.
Pageof 38

Showing results (141-150 of 376) with videos related to

Sort By:
Pageof 38
European Heart Journal|January 14, 2016
Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 studyJohn J P Kastelein, Steven E Nissen, Daniel J Rader, et al.
Journal of Clinical Lipidology|October 6, 2018
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, John R Guyton, Gisle Langslet, et al.
Circulation. Genomic and Precision Medicine|December 19, 2018
A Deep Intronic Variant in LDLR in Familial HypercholesterolemiaLaurens F Reeskamp, Merel L Hartgers, Jorge Peter, et al.
Journal of Clinical Lipidology|July 29, 2018
Ethnic differences in plasma lipid levels in a large multiethnic cohort: The HELIUS studyKatia Gazzola, Marieke B Snijder, G Kees Hovingh, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|July 9, 2025
Therapeutic drug monitoring of piperacillin: Agreement between quantitative nuclear magnetic resonance spectroscopy and liquid chromatography with tandem mass spectrometryAlexander Dejaco, Michael Paal, Michael Gruber, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|November 19, 2016
Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief ReportRutger Verbeek, Marjorie Boyer, S Matthijs Boekholdt, et al.
Journal of Clinical Lipidology|October 26, 2017
Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemiaG Kees Hovingh, Frederick J Raal, Ricardo Dent, et al.
Journal of Lipid Research|April 18, 2003
The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemiaG Kees Hovingh, Michel J A Van Wijland, Alison Brownlie, et al.
Circulation Research|July 19, 2014
Mutations in STAP1 are associated with autosomal dominant hypercholesterolemiaSigrid W Fouchier, Geesje M Dallinga-Thie, Joost C M Meijers, et al.
Therapeutic Drug Monitoring|September 16, 2016
Variable Linezolid Exposure in Intensive Care Unit Patients-Possible Role of Drug-Drug InteractionsChristoph Töpper, Cathérine L Steinbach, Christoph Dorn, et al.
Pageof 38